Immunologic basis for allopurinol-induced severe cutaneous adverse reactions: HLA-B∗58:01-restricted activation of drug-specific T cells and molecular interaction: To the editor

Journal of Allergy and Clinical Immunology

Volumn 135, Issue 4, 2015, Pages 1063-1065.e5

  Lin, Chia Hsien ^a,b   Chen, Jung Kuei ^b   Ko, Tai Ming ^b   Wei, Chun Yu ^b   Wu, Jer Yuarn ^b   Chung, Wen Hung ^d   Chen, Shih Yang ^e   Liao, You Di ^b   Hung, Shuen Iu ^c   Chen, Yuan Tsong ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^e Department of Surgery   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; COMPLEMENT COMPONENT C1R; HLA B ANTIGEN; OXIPURINOL; T LYMPHOCYTE RECEPTOR;

ALLELE; ANTIBODY AFFINITY; ANTIGEN PRESENTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; CROSS REACTION; DRESS SYNDROME; DRUG BINDING SITE; DRUG CYTOTOXICITY; DRUG INDUCED DISEASE; GENE ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LETTER; LYMPHOBLASTOID CELL; MOLECULAR INTERACTION; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; STEVENS JOHNSON SYNDROME; SURFACE PLASMON RESONANCE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TOXIC EPIDERMAL NECROLYSIS; ADVERSE DRUG REACTION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PHARMACOGENETICS;

ALLOPURINOL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HLA-B ANTIGENS; HUMANS; LYMPHOCYTE ACTIVATION; PHARMACOGENETICS; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES;

EID: 84926164079     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2014.09.041     Document Type: Article

References (6)

1. R. Terkeltaub Update on gout: new therapeutic strategies and options Nat Rev Rheumatol 6 2010 30 38
2. S.I. Hung, W.H. Chung, L.B. Liou, C.C. Chu, M. Lin, and H.P. Huang HLA-B∗5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol Proc Natl Acad Sci U S A 102 2005 4134 4139
3. E.J. Phillips, W.H. Chung, M. Mockenhaupt, J.C. Roujeau, and S.A. Mallal Drug hypersensitivity: pharmacogenetics and clinical syndromes J Allergy Clin Immunol 127 suppl 2011 S60 S66
4. J. Yun, J. Mattsson, K. Schnyder, S. Fontana, C.R. Largiader, and W.J. Pichler Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response Clin Exp Allergy 43 2013 1246 1255
5. J. Yun, M.J. Marcaida, K.K. Eriksson, H. Jamin, S. Fontana, and W.J. Pichler Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B∗58:01 J Immunol 192 2014 2984 2993
6. Y. Zhang, H. Mei, Q. Wang, J. Xie, J. Lv, and X. Pan Peptide binding specificities of HLA-B∗5701 and B∗5801 Sci China Life Sci 55 2012 818 825